These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22984076)

  • 1. Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.
    Chou CK; Schietinger A; Liggitt HD; Tan X; Funk S; Freeman GJ; Ratliff TL; Greenberg NM; Greenberg PD
    J Immunol; 2012 Oct; 189(8):3936-46. PubMed ID: 22984076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.
    Zhang Q; Yang XJ; Kundu SD; Pins M; Javonovic B; Meyer R; Kim SJ; Greenberg NM; Kuzel T; Meagher R; Guo Y; Lee C
    Mol Cancer Ther; 2006 Jul; 5(7):1733-43. PubMed ID: 16891459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
    Wallace A; Kapoor V; Sun J; Mrass P; Weninger W; Heitjan DF; June C; Kaiser LR; Ling LE; Albelda SM
    Clin Cancer Res; 2008 Jun; 14(12):3966-74. PubMed ID: 18559619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
    Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.
    Diener KR; Woods AE; Manavis J; Brown MP; Hayball JD
    Lab Invest; 2009 Feb; 89(2):142-51. PubMed ID: 19079323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent.
    Olurinde MO; Shen CH; Drake A; Bai A; Chen J
    Cell Mol Immunol; 2011 Sep; 8(5):415-23. PubMed ID: 21666707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.
    Ward-Kavanagh LK; Zhu J; Cooper TK; Schell TD
    Cancer Immunol Res; 2014 Aug; 2(8):777-88. PubMed ID: 24801834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
    Shafer-Weaver KA; Anderson MJ; Stagliano K; Malyguine A; Greenberg NM; Hurwitz AA
    J Immunol; 2009 Oct; 183(8):4848-52. PubMed ID: 19801511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
    Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
    J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
    Bai A; Higham E; Eisen HN; Wittrup KD; Chen J
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13003-8. PubMed ID: 18723683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8
    Chen X; Wang L; Li P; Song M; Qin G; Gao Q; Zhang Z; Yue D; Wang D; Nan S; Qi Y; Li F; Yang L; Huang L; Zhang M; Zhang B; Gao Y; Zhang Y
    Int J Cancer; 2018 Nov; 143(10):2561-2574. PubMed ID: 29981155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
    Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
    Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
    Dawicki W; Bertram EM; Sharpe AH; Watts TH
    J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
    Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
    Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
    Ryan CM; Schell TD
    J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
    Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
    J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.
    Bendle GM; Linnemann C; Bies L; Song JY; Schumacher TN
    J Immunol; 2013 Sep; 191(6):3232-9. PubMed ID: 23940272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
    Ahmadzadeh M; Rosenberg SA
    J Immunol; 2005 May; 174(9):5215-23. PubMed ID: 15843517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.